Biogen (BIIB) Current Deferred Revenue (2010 - 2012)

Biogen (BIIB) has reported Current Deferred Revenue for 3 consecutive years, with $110.3 million the latest figure, recorded in Q2 2012.

• In Q2 2012, Current Deferred Revenue changed N/A year-over-year to $110.3 million; the TTM figure through Jun 2012 stood at $110.3 million (changed N/A YoY), while the FY2011 annual figure was $69.6 million, up 68.52% from the prior year.
• Current Deferred Revenue came in at $110.3 million for Q2 2012 at Biogen, up from $96.0 million in the prior quarter.
• The five-year high for Current Deferred Revenue was $110.3 million in Q2 2012, with the low at $41.3 million in Q4 2010.
• Average Current Deferred Revenue over 3 years is $79.3 million, with a median of $82.8 million recorded in 2011.
• The largest YoY upside for Current Deferred Revenue was 68.52% in 2011 against a maximum downside of 68.52% in 2011.
• Year by year, Current Deferred Revenue stood at $41.3 million in 2010, then jumped by 68.52% to $69.6 million in 2011, then surged by 58.48% to $110.3 million in 2012.
• According to Business Quant data, Current Deferred Revenue over the past three periods registered $110.3 million, $96.0 million, and $69.6 million for Q2 2012, Q1 2012, and Q4 2011 respectively.